CSPC Pharmaceutical Group Limited (1093.HK)
- Previous Close
5.860 - Open
5.790 - Bid 5.770 x --
- Ask 5.790 x --
- Day's Range
5.650 - 5.820 - 52 Week Range
5.200 - 8.260 - Volume
60,339,858 - Avg. Volume
40,480,994 - Market Cap (intraday)
68.667B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
10.89 - EPS (TTM)
0.530 - Earnings Date May 23, 2024 - May 27, 2024
- Forward Dividend & Yield 0.28 (4.85%)
- Ex-Dividend Date May 31, 2024
- 1y Target Est
9.71
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
www.cspc.com.hk23,500
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 1093.HK
Performance Overview: 1093.HK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1093.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1093.HK
Valuation Measures
Market Cap
68.67B
Enterprise Value
55.27B
Trailing P/E
10.78
Forward P/E
10.05
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.01
Price/Book (mrq)
1.91
Enterprise Value/Revenue
1.76
Enterprise Value/EBITDA
7.45
Financial Highlights
Profitability and Income Statement
Profit Margin
18.67%
Return on Assets (ttm)
9.96%
Return on Equity (ttm)
18.22%
Revenue (ttm)
31.45B
Net Income Avi to Common (ttm)
5.87B
Diluted EPS (ttm)
0.530
Balance Sheet and Cash Flow
Total Cash (mrq)
13.76B
Total Debt/Equity (mrq)
2.02%
Levered Free Cash Flow (ttm)
--